Brief: Cassava Sciences Q4 Basic EPS USD -0.5
28/02/2024 14:14
Feb 28 (Reuters) - Cassava Sciences Q4 operating income USD -22.789 million. * Q4 net income USD -20.919 million * Q4 operating expenses USD 22.789 million
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing